DOCSLIB.ORG

Enzyme Defects in the Sphingolipidoses and Their Application to Diagnosis*

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enzyme Defects in the Sphingolipidoses and Their Application to Diagnosis* A n n a l s o f C linical Laboratory Science, Vol. 2, No. 4 Copyright © 1972, I n s t i t u t e for Clinical Science Enzyme Defects in the Sphingolipidoses and Their Application to Diagnosis* ROSCOE O. BRADY, M.D. Developmental and Metabolic Neurology Branch National Institute of Neurological Diseases and Stroke National Institutes of Health Bethesda, MD 20014 Chronicle methods for detecting fetuses afflicted with The first clinical indication of a heritable each of the nine now known lipid storage diseases sufficiently early in pregnancy for disorder of lipid metabolism appeared just precise genetic counseling. This paper is a over 90 years ago with Warren Tay’s de­ brief review of how these developments scription of changes in the macular region came about. Moreover, an effort is made to of the eyes of children.33 Six years later, anticipate further progress in this family Bernard Sachs reported that patients with of genetic diseases. these eye lesions were also severely re­ tarded.28 In time this condition was named Tay-Sachs disease. However, most of the Clinical Manifestations of Lipid pioneering developments in the field of Storage Diseases lipid storage diseases have arisen from in­ The signs and symptoms of patients with tensive investigations in another of these the sphingolipidoses are quite varied and conditions called Gaucher’s disease. The are functions of the nature of the accumu­ first clinical description of patients with lating lipid and the particular organs and this syndrome postdated Tay’s communica­ tissues involved in the storage process tion by only a year.14 The chemical struc­ (table I). The development of the central ture of the stored lipid was first identified nervous system may be impaired in eight in Gaucher’s disease,1 and the nature of of the nine known disorders; the apparent the explicit metabolic derangement was single exception is Fabry’s disease in which elucidated first in this sphingolipodys- neuralgias and peripheral neuropathy are trophy.7’9 Through this demonstration, an frequently encountered. If the underlying unbroken precedent regarding the under­ metabolic abnormality is less severe than a lying metabolic defect in all of the sphingo­ total loss of the requisite enzyme, patients lipidoses was established. Much practical may escape cerebral damage. Patients with benefit followed this demonstration, includ­ the so-called “juvenile” and “adult” forms ing (1) accurate diagnostic tests, (2) pro­ of Gaucher’s disease are frequently en­ cedures for identifying heterozygous car­ countered in medical clinics because of riers of the lipidoses, and (3) reliable organomegaly, thrombocytopenia, or patho­ logic fractures of the long bones and verte­ * Presented at the Applied Seminar on the Clin­ brae in whom mental function is perfectly ical Pathology of the Lipids, November, 1971. normal. Improved diagnostic procedures 285 286 BRADY TABLE I M a j o r S i g n s a n d S y m p t o m s o f t h e S phingolipidoses Gaucherrs disease Mental retardation (infantile form only), hepatosplenomegaly, hip and long bone involvement, Oil-red-O and PAS-positive lipid-laden (Gaucher) cells in bone marrow, increased serum acid phosphatase, mild anemia, and thrombocytopenia Niemann-Pick disease Generally similar to Gaucher's disease? 30 percent with cherry-red spot in macula; marrow cells (foam cells) stain for both lipid and phosphorus, cachexia Globoid leukodystrophy Mental retardation? almost total absence of myelin, severe (Krabbe's disease) gliosis, and multinucleated "globoid bodies” in white matter Metachromatic leukodystrophy Mental retardation? psychological disturbances (adult form)? decreased nerve conduction time? nerve biopsy shows yellow- brown droplets when stained with cresyl violet (metachromasia) Ceramide lactoside lipidosis Slowly progressing CNS impairment? hepatosplenomegaly; macrocytic anemia, leukopenia and thrombocytopenia due to involvement of bone marrow and spleen Fabry's disease Reddish-purple maculo-papular rash in umbilical, inguinal and scrotal areas? renal impairment? corneal opacities; peripheral neuralgias and abnormalities of EKG Tay-Sachs disease Mental retardation, amaurosis, cherry-red spot in macula, macrocephaly, neuronal cells distended with "membranous cytoplasmic bodies” Generalized gangliosidosis Mental retardation, cherry-red spot in macula (50 percent of patients), hepatosplenomegaly, foam cells in bone marrow, rarefaction of all bones and skeletal deformities now available have permitted the conclu­ X-chromosome, and therefore only the fe­ sive identification of patients with Nie- male need be a carrier in order to have a mann-Pick disease also without neuronal male child affected with this disorder. Half involvement. Except for Fabry’s disease of her sons will have the disease, 50 percent and Tay-Sachs disease, hepatosplenomegaly of her daughters will be heterozygous, and is usually observed in patients with a the others will not be involved. In order sphingolipidosis. Large lipid-laden histio­ to produce an offspring afflicted with one cytes are present in the bone marrow and of the other lipid storage diseases, both elsewhere throughout the reticuloendothe­ parents must be heterozygotes. Of four lial system. In Fabry’s disease, there is an children born to such parents on a statis­ accumulation of glycolipid in the glomeruli tical basis, one child will have the disease, of the kidney, the vascular endothelium, two will be heterozygotes, and one will be and lymphatics. In patients with Tay-Sachs uninvolved. Obviously in these disorders, disease, only the neuronal cells in the both of the sexes are equally affected. central nervous system and myenteric There are interesting clinical subtleties plexus are extensively involved.34 regarding heterozygotes. Female carriers for Fabry’s disease may have varying de­ Genetics grees of ophthalmological difficulties pri­ All of the lipid storage diseases which marily affecting the cornea. By and large, are known at the present time are trans­ heterozygotes for the other lipidoses are mitted as autosomal recessive traits with symptom-free and some speculation has the exception of Fabry’s disease. The muta­ even appeared regarding the possibility that tion in Fabry’s disease is linked to the survival advantage may be a consequence ENZYME DEFECTS IN THE SPHINGOLIPIDOSES 287 of being heterozygous for Tay-Sachs dis­ lipid component of brain.36 It was there­ ease.31 fore necessary to determine whether gluco­ cerebroside was synthesized in patients Metabolic Derangements with Gaucher’s disease instead of galacto- At least five biochemical aspects are con­ cerebroside because of faulty galactose me­ stant features of all of the lipid storage tabolism. This possibility was dispelled by diseases: (1) in all of these disorders there Thannhauser in 195035 by his demonstrat­ is an accumulation of a complex lipid in ing that there was no abnormality of galac­ various tissues of the body; (2) a portion tose tolerance in Gaucher patients. We of the structure of all of the involved lipids confirmed Thannhauser’s observation and is similar and it is called ceramide (N-fatty set about to try to decide between the acyl sphingosine) following two alternatives: (1) the possi­ bility of an overproduction of a normally [CHs—(CH2) 12—CH=CH—CH (OH) minor tissue component, or (2) an impair­ —CH( NHCOR)—CH2OH]; ment of catabolism of the accumulating glycolipid. Experiments were carried out in (3) the rate of synthesis of the stored lipid 1959 dealing with the biosynthesis of cere- in patients with these disorders is com­ brosides in spleen tissue slices obtained parable to that in non-involved humans; from various control human sources and (4) the enzymatic defect in each of the from patients with Gaucher’s disease. diseases is a deficiency of a specific hydro­ These investigations revealed that there lytic enzyme required for the degradation was no increase in the rate of cerebroside of the acculating lipid; and (5) the degree formation in the tissues obtained from of attenuation of enzymatic activity is simi­ Gaucher’s patients.37 This observation led lar in all of the tissues of an affected indi­ to the idea that a deficiency of a catabolic vidual. These important concepts should enzyme was responsible for the accumula­ be kept in mind since they constitute an tion of the lipid. In 1965, it was shown important basis for investigations which conclusively that the activity of glucocere­ have provided impressive advances towards broside /J-glucosidase was drastically dimin­ the understanding and management of the ished in tissue preparations obtained from sphingolipidos es. patients with Gaucher’s disease compared The best documentation of the funda­ with the activity of this enzyme in normal mental biochemical aspects of lipid storage humans.7’9 These experiments provided the diseases has evolved over the years in the foundation for understanding the nature of course of investigations on the etiology of the metabolic abnormality in all of the Gaucher’s disease. The lipid which accu­ presently known lipid storage diseases; viz, mulates in patients with this disease is a deficiency of a specific hydrolytic enzyme called glucocerebroside. It consists of a which catalyzes the degradation of the ac­ single molecule of glucose linked by a p- cumulating lipid. Following this initial glycosidic bond to carbon atom 1 of cera­ demonstration, the underlying abnormal mide (figure 1). In order to elucidate the enzymology was soon established for meta- nature of the metabolic abnormality in chromatic leukodystrophy,22 Niemann-Pick Gaucher’s disease, a decision was required disease,8 and Fabry’s disease.5 In time, the which involved at least three separate pos­ specific enzyme deficiency was identified sibilities. The first was the formation of in the remaining lipid storage disease (fig­ an abnormal cerebroside due to an altera­ ure 1). The metabolic lesion in the lipi­ tion of carbohydrate metabolism. It had doses are quite straight-forward with the been known since 1901 that galactocere- exception of Tay-Sachs disease.
Load more

Recommended publications
  • Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1758 (2006) 2057–2079 www.elsevier.com/locate/bbamem Review Sphingolipid metabolism diseases ⁎ Thomas Kolter, Konrad Sandhoff Kekulé-Institut für Organische Chemie und Biochemie der Universität, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany Received 23 December 2005; received in revised form 26 April 2006; accepted 23 May 2006 Available online 14 June 2006 Abstract Human diseases caused by alterations in the metabolism of sphingolipids or glycosphingolipids are mainly disorders of the degradation of these compounds. The sphingolipidoses are a group of monogenic inherited diseases caused by defects in the system of lysosomal sphingolipid degradation, with subsequent accumulation of non-degradable storage material in one or more organs. Most sphingolipidoses are associated with high mortality. Both, the ratio of substrate influx into the lysosomes and the reduced degradative capacity can be addressed by therapeutic approaches. In addition to symptomatic treatments, the current strategies for restoration of the reduced substrate degradation within the lysosome are enzyme replacement therapy (ERT), cell-mediated therapy (CMT) including bone marrow transplantation (BMT) and cell-mediated “cross correction”, gene therapy, and enzyme-enhancement therapy with chemical chaperones. The reduction of substrate influx into the lysosomes can be achieved by substrate reduction therapy. Patients suffering from the attenuated form (type 1) of Gaucher disease and from Fabry disease have been successfully treated with ERT. © 2006 Elsevier B.V. All rights reserved. Keywords: Ceramide; Lysosomal storage disease; Saposin; Sphingolipidose Contents 1. Sphingolipid structure, function and biosynthesis ..........................................2058 1.1.
    [Show full text]
  • Management of Patients with Cardiac Manifestations
    MANAGEMENT OF PATIENTS WITH CARDIAC MANIFESTATIONS KDIGOAleš Linhart First School of Medicine Charles University Prague Czech Republic Disclosure of Interests Speaker´s honoraria, travel reimbursements and consultancy honoraria from: • Genzyme • Shire HGT • Amicus Therapeutics • Actelion KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland KDIGO HEART FAILURE KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland Diffuse LVH on MRI in Fabry disease KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland Data source: General University Hospital, Prague Cardiac symptoms in AFD LV hypertrophy absent LV hypertrophy present KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland Linhart et al., European Heart Journal 2007 28(10):1228-1235 Fabry left ventricular function KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland N-Terminal Pro-BNP in Diagnosis of Cardiac Involvement in AFD Patients 117 patients, (age 48 ± 15 years, 46.2% men) - BNP elevated in 57% KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland Coats et al., Am J Cardiol. 2013;111:111-7. Diagnosis of heart failure KDIGO ESC GuidelinesKDIGO Controversies for the Conference diagnosis on Fabry and Disease treatment | October of 15-17, acute 2015 and | Dublin, chronic Ireland heart failure 2012. European Heart Journal 2012; 33: 1787–1847 Trials in heart failure with preserved ejection fraction DIG-PEF Digoxin Trend to ↓ hospitalizations ↑ UAP CHARM-PRESERVED Candesartan Trend ↓ hospitalizations I-PRESERVE Irbesartan No effect PEP-CHF PerindoprilKDIGO↓ hospitalizations SENIORS HF-PEF Nebivolol Trend to ↓ Clinical subgroup complications TOP-CAT Spironolactone Effective in subjects recruited in USA and LATAM KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland J Am Coll Cardiol.
    [Show full text]
  • Attenuation of Ganglioside GM1 Accumulation in the Brain of GM1 Gangliosidosis Mice by Neonatal Intravenous Gene Transfer
    Gene Therapy (2003) 10, 1487–1493 & 2003 Nature Publishing Group All rights reserved 0969-7128/03 $25.00 www.nature.com/gt RESEARCH ARTICLE Attenuation of ganglioside GM1 accumulation in the brain of GM1 gangliosidosis mice by neonatal intravenous gene transfer N Takaura1, T Yagi2, M Maeda2, E Nanba3, A Oshima4, Y Suzuki5, T Yamano1 and A Tanaka1 1Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan; 2Department of Neurobiology and Anatomy, Osaka City University Graduate School of Medicine, Osaka, Japan; 3Gene Research Center, Tottori University, Yonago, Japan; 4Department of Pediatrics, Takagi Hospital, Saitama, Japan; and 5Pediatrics, Clinical Research Center, Nasu Institute for Developmental Disabilities, International University of Health and Welfare, Ohtawara, Japan A single intravenous injection with 4 Â 107 PFU of recombi- ganglioside GM1 was above the normal range in all treated nant adenovirus encoding mouse b-galactosidase cDNA to mice, which was speculated to be the result of reaccumula- newborn mice provided widespread increases of b-galacto- tion. However, the values were still definitely lower in most of sidase activity, and attenuated the development of the the treated mice than those in untreated mice. In the disease including the brain at least for 60 days. The b- histopathological study, X-gal-positive cells, which showed galactosidase activity showed 2–4 times as high a normal the expression of exogenous b-galactosidase gene, were activity in the liver and lung, and 50 times in the heart. In the observed in the brain. It is noteworthy that neonatal brain, while the activity was only 10–20% of normal, the administration via blood vessels provided access to the efficacy of the treatment was distinct.
    [Show full text]
  • The Multiple Roles of Sphingomyelin in Parkinson's Disease
    biomolecules Review The Multiple Roles of Sphingomyelin in Parkinson’s Disease Paola Signorelli 1 , Carmela Conte 2 and Elisabetta Albi 2,* 1 Biochemistry and Molecular Biology Laboratory, Health Sciences Department, University of Milan, 20142 Milan, Italy; [email protected] 2 Department of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy; [email protected] * Correspondence: [email protected] Abstract: Advances over the past decade have improved our understanding of the role of sphin- golipid in the onset and progression of Parkinson’s disease. Much attention has been paid to ceramide derived molecules, especially glucocerebroside, and little on sphingomyelin, a critical molecule for brain physiopathology. Sphingomyelin has been proposed to be involved in PD due to its presence in the myelin sheath and for its role in nerve impulse transmission, in presynaptic plasticity, and in neurotransmitter receptor localization. The analysis of sphingomyelin-metabolizing enzymes, the development of specific inhibitors, and advanced mass spectrometry have all provided insight into the signaling mechanisms of sphingomyelin and its implications in Parkinson’s disease. This review describes in vitro and in vivo studies with often conflicting results. We focus on the synthesis and degradation enzymes of sphingomyelin, highlighting the genetic risks and the molecular alterations associated with Parkinson’s disease. Keywords: sphingomyelin; sphingolipids; Parkinson’s disease; neurodegeneration Citation: Signorelli, P.; Conte, C.; 1. Introduction Albi, E. The Multiple Roles of Sphingomyelin in Parkinson’s Parkinson’s disease (PD) is the second most common neurodegenerative disease (ND) Disease. Biomolecules 2021, 11, 1311. after Alzheimer’s disease (AD). Recent breakthroughs in our knowledge of the molecular https://doi.org/10.3390/ mechanisms underlying PD involve unfolded protein responses and protein aggregation.
    [Show full text]
  • The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue
    The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue JOHN F. TALLMAN, WILLIAM G. JOHNSON, and ROSCOE 0. BRADY From the Developmental and Metabolic Neurology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland 20014, and the Department of Biochemistry, Georgetown University School of Medicine, Washington, D. C. 20007 A B S T R A C T The catabolism of Tay-Sachs ganglioside, date fronm the 19th century and over 599 cases have been N-acetylgalactosaminyl- (N-acetylneuraminosyl) -galac- reported (1). Onset of the disease is in the first 6 months tosylglucosylceramide, has been studied in lysosomal of life and is characterized by apathy, hyperacusis, motor preparations from normal human brain and brain ob- weakness, and appearance of a macular cherry-red spot tained at biopsy from Tay-Sachs patients. Utilizing Tay- in the retina. Seizures and progressive mental deteriora- Sachs ganglioside labeled with '4C in the N-acetylgalac- tion follow with blindness, deafness, and spasticity, lead- tosaminyl portion or 3H in the N-acetylneuraminosyl ing to a state of decerebrate rigidity. These infants usu- portion, the catabolism of Tay-Sachs ganglioside may be ally die by 3 yr of age (2). initiated by either the removal of the molecule of A change in the chemical composition of the brain of N-acetylgalactosamine or N-acetylneuraminic acid. The such patients was first detected by Klenk who showed activity of the N-acetylgalactosamine-cleaving enzyme that there was an increase in the ganglioside content (hexosaminidase) is drastically diminished in such compared with normal human brain tissue (3).
    [Show full text]
  • GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
    International Journal of Molecular Sciences Review GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies Andrés Felipe Leal 1 , Eliana Benincore-Flórez 1, Daniela Solano-Galarza 1, Rafael Guillermo Garzón Jaramillo 1 , Olga Yaneth Echeverri-Peña 1, Diego A. Suarez 1,2, Carlos Javier Alméciga-Díaz 1,* and Angela Johana Espejo-Mojica 1,* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia; [email protected] (A.F.L.); [email protected] (E.B.-F.); [email protected] (D.S.-G.); [email protected] (R.G.G.J.); [email protected] (O.Y.E.-P.); [email protected] (D.A.S.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá 110231, Colombia * Correspondence: [email protected] (C.J.A.-D.); [email protected] (A.J.E.-M.); Tel.: +57-1-3208320 (ext. 4140) (C.J.A.-D.); +57-1-3208320 (ext. 4099) (A.J.E.-M.) Received: 6 July 2020; Accepted: 7 August 2020; Published: 27 August 2020 Abstract: GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay–Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic of GM2 gangliosidoses patients that include neurodevelopment alterations, neuroinflammation, and neuronal apoptosis. Currently, there is not approved therapy for GM2 gangliosidoses, but different therapeutic strategies have been studied including hematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction therapy, pharmacological chaperones, and gene therapy.
    [Show full text]
  • Hyperglycopeptiduria in Genetic Mucolipidoses
    Tohoku J. exp. Med., 1974, 112, 373-380 Hyperglycopeptiduria in Genetic Mucolipidoses TADAO ORII, TAKAMICHI CHIBA, RYOJI MINAMI, KAZUKO S UKEGAWA and TooRu NAKAO Department of Pediatrics, Sapporo Medical College, Sapporo ORII, T., CHmA, T., MINAMI, R., SUKEUAWA,K. and NAKAO, T. Hyper glycopeptiduria in Genetic Mucolipidoses. Tohoku J. exp. Med., 1974, 112 (4), 373-380 -Urinary cetylpyridinium chloride (CPC)-precipitates and non-CPC- precipitates in normal male children and seven patients with a new type of mucolipidosis, GM1-gangliosidosis type 1, I-cell disease, Hurler syndrome, Morquio syndrome, Gaucher's disease adult type and Tay-Sachs disease were studied using several methods including Sephadex G-25 gel filtration, ECTEOLA-cellulose column chromatography and enzymatic digestion with chondroitinase ABC. 1) Considerable amounts of glycopeptide fractions were detected in the urine of the patients with a new type of mucolipidosis, Gm1-gangliosidosis type 1, I-cell disease and also Gaucher's disease adult type compared with that of normal male children and other patients. 2) The total acid mucopolysaccharides excreted into the urine from two patients with Hurler syndrome and Morquio syndrome were much higher than those excreted in normal male children and other patients. 3) Large amounts of the chondroitinase ABC-resistant acid mucopolysaccharides were found in the urine of patients with Hurler syndrome, Morquio syndrome and Gm,-gangliosidosis type 1. mucolipidoses; glycopeptiduria; Gaucher's disease A group of storage disease which exhibits signs and symptoms of both mucopolysaccharidoses and sphingolipidoses has tentatively been classified as the mucolipidoses by Spranger and Wiedemann (1970). With the exception of the Austin type of sulfatidosis, it has been reported by several workers that the patients with mucolipidosis generally show normal urinary excretion of uronic acid-containing mucopolysaccharides.
    [Show full text]
  • The Nature of Mutation in Krabbe Disease
    Am J Hum Genet 30:644-652, 1978 The Nature of Mutation in Krabbe Disease YOAV BEN-YOSEPH,1 MELINDA HUNGERFORD, AND HENRY L. NADLER Krabbe disease (globoid cell leukodystrophy) is a disorder of galactolipid metabolism, inherited in an autosomal recessive manner [1]. Onset in early infancy is followed by rapidly progressive degeneration of the central nervous system, ending in death before the age of 2 years. The primary defect has been ascribed to a deficiency of galactosylceramide /3-galactosidase activity [2]. In addition, a deficiency of /3- galactosidase activities towards psychosine (galactosylsphingosine) [3], monogalac- tosyl diglyceride [4], and lactosylceramide [5] have been reported. The inability to degrade these substrates, found in tissues of children who died of Krabbe disease, indicates that the same enzyme may be acting on the four galactolipids. These activities are, however, normal in patients with GM, gangliosidosis. Hydrolysis of lactosyl- ceramide under different assay conditions [6] and /3-galactosidase activities towards GM, ganglioside, asialo-GMl ganglioside, and asialofetuin (ASF) are deficient in GM, gangliosidosis, but normal in Krabbe disease [7]. Thus, the mutation in Krabbe disease is not allelic with the GM, gangliosidosis mutation, and the observation that antibodies to GM, /3-galactosidase do not precipitate the activities of galactosylceramide 38- galactosidase [8, 9] supports the conclusion that these two /3-galactosidase enzymes are different proteins coded by separate loci. The present study defines the nature of the mutation in Krabbe disease. Using antibodies evoked against the normal galactosylceramide ,3-galactosidase enzyme purified from placenta, we found normal quantities of antigenically cross reacting material of the inactive mutant enzyme in brain, liver, and skin fibroblasts of patients with Krabbe disease.
    [Show full text]
  • Correction of the Enzymic Defect in Cultured Fibroblasts from Patients with Fabry's Disease: Treatment with Purified A-Galactosidase from Ficin
    Pediat. Res. 7: 684-690 (1973) Fabry's disease genetic disease ficin trihexosylceramide a-galactosidase Correction of the Enzymic Defect in Cultured Fibroblasts from Patients with Fabry's Disease: Treatment with Purified a-Galactosidase from Ficin GLYN DAWSON1341, REUBEN MATALON, AND YU-TEH LI Departments of Pediatrics and Biochemistry, Joseph P. Kennedy, Jr., Mental Retardation Research Center, University of Chicago, Chicago, Illinois, USA Extract Cultured skin fibroblasts from patients with Fabry's disease showed the characteristic a-galactosidase deficiency and accumulated a four- to sixfold excess of trihexosylceram- ide (GL-3). To demonstrate the correction, cells previously labeled with U-14G-glucose were grown in medium containing a purified a-galactosidase preparation obtained from ficin. The results demonstrated that a-galactosidase was taken up rapidly from the medium and that, despite its apparent instability in the fibroblasts, it was able to become incorporated into lysosomes and catabolize the stored trihexosylceramide. These findings support the reports of therapeutic endeavors by renal transplantation and plasma infusion in Fabry's disease and suggest the extension of such studies to other related disorders in which the cultured skin fibroblasts are chemically abnormal, namely, Gaucher's disease, lactosylceramidosis, and GM2-gangliosidosis type II. Speculation It may be possible to replace the specific missing lysosomal hydrolase in various sphingolipidoses and other storage diseases. Although we do not propose to effect enzyme replacement therapy in vivo with a plant enzyme, such studies in tissue culture are valid, and eventually human a-galactosidase, of comparable activity and purity, will become available. Introduction tially unaffected, periodic crises of pain occur and this may be explained by the accumulation of GL-3 in the Fabry's disease (angiokeratoma corporis diffusum uni- dorsal root ganglia [21, 23].
    [Show full text]
  • HHS Public Access Author Manuscript
    HHS Public Access Author manuscript Author Manuscript Author ManuscriptJ Registry Author Manuscript Manag. Author Author Manuscript manuscript; available in PMC 2015 May 11. Published in final edited form as: J Registry Manag. 2014 ; 41(4): 182–189. Exclusion of Progressive Brain Disorders of Childhood for a Cerebral Palsy Monitoring System: A Public Health Perspective Richard S. Olney, MD, MPHa, Nancy S. Doernberga, and Marshalyn Yeargin-Allsopp, MDa aNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC) Abstract Background—Cerebral palsy (CP) is defined by its nonprogressive features. Therefore, a standard definition and list of progressive disorders to exclude would be useful for CP monitoring and epidemiologic studies. Methods—We reviewed the literature on this topic to 1) develop selection criteria for progressive brain disorders of childhood for public health surveillance purposes, 2) identify categories of disorders likely to include individual conditions that are progressive, and 3) ascertain information about the relative frequency and natural history of candidate disorders. Results—Based on 19 criteria that we developed, we ascertained a total of 104 progressive brain disorders of childhood, almost all of which were Mendelian disorders. Discussion—Our list is meant for CP surveillance programs and does not represent a complete catalog of progressive genetic conditions, nor is the list meant to comprehensively characterize disorders that might be mistaken for cerebral
    [Show full text]
  • Mouse Model of GM2 Activator Deficiency Manifests Cerebellar Pathology and Motor Impairment
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 8138–8143, July 1997 Medical Sciences Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment (animal modelyGM2 gangliosidosisygene targetingylysosomal storage disease) YUJING LIU*, ALEXANDER HOFFMANN†,ALEXANDER GRINBERG‡,HEINER WESTPHAL‡,MICHAEL P. MCDONALD§, KATHERINE M. MILLER§,JACQUELINE N. CRAWLEY§,KONRAD SANDHOFF†,KINUKO SUZUKI¶, AND RICHARD L. PROIA* *Section on Biochemical Genetics, Genetics and Biochemistry Branch, National Institute of Diabetes and Digestive and Kidney Diseases, ‡Laboratory of Mammalian Genes and Development, National Institute of Child Health and Development, and §Section on Behavioral Neuropharmacology, Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892; †Institut fu¨r Oganische Chemie und Biochemie der Universita¨tBonn, Gerhard-Domagk-Strasse 1, 53121 Bonn, Germany; and ¶Department of Pathology and Laboratory Medicine, and Neuroscience Center, University of North Carolina, Chapel Hill, NC 27599 Communicated by Stuart A. Kornfeld, Washington University School of Medicine, St. Louis, MO, May 12, 1997 (received for review March 21, 1997) ABSTRACT The GM2 activator deficiency (also known as disorder, the respective genetic lesion results in impairment of the AB variant), Tay–Sachs disease, and Sandhoff disease are the the degradation of GM2 ganglioside and related substrates. major forms of the GM2 gangliosidoses, disorders caused by In humans, in vivo GM2 ganglioside degradation requires the defective degradation of GM2 ganglioside. Tay–Sachs and Sand- GM2 activator protein to form a complex with GM2 ganglioside. hoff diseases are caused by mutations in the genes (HEXA and b-Hexosaminidase A then is able to interact with the activator- HEXB) encoding the subunits of b-hexosaminidase A.
    [Show full text]
  • Mucopolysaccharidoses and Mucolipidoses
    J Clin Pathol: first published as 10.1136/jcp.s3-8.1.64 on 1 January 1974. Downloaded from J. clin. Path., 27, Suppl. (Roy. Coll. Path.), 8, 64-93 Mucopolysaccharidoses and mucolipidoses F. VAN HOOF From the Laboratoire de Chimie Physiologique, Universite Catholique de Louvain, and International Institute of Cellular and Molecular Pathology, Brussels, Belgium Many different syndromes are classified as muco- THE CHEMICAL ERA polysaccharidoses, and, despite remarkable progress Chemical studies, performed mainly by groups in the biochemical understanding of these diseases, working with A. Dorfman, in Chicago and K. much remains to be learned and many cases still Meyer, in New York, have provided most of the escape classification. new knowledge in the field by analysis of tissue and Mucopolysaccharidoses are inborn storage dis- urinary mucopolysaccharides in patients (Dorfman eases, characterized by a complex accumulation of and Lorincz, 1957; Meyer, Grumbach, Linker, and mucopolysaccharides and of glycolipids within the Hoffman, 1958; Meyer, Hoffman, Linker, lysosomes. Sixteen human diseases correspond to Grumbach, and Sampson, 1959). These provided the this definition, of which nine have been presently basis for the subdivision of the 'Hurler syndrome' explained by the deficiency of an acid hydrolase. into six subgroups (McKusick, Kaplan, Wise, They are somewhat arbitrarily divided into muco- Hanley, Suddarth, Sevick, and Maumanee, 1965). polysaccharidoses and mucolipidoses. In muco- The possibility that mucopolysaccharidoses could polysaccharidoses, mucopolysaccharides are the result from an excessive biosynthesis of muco- main storage substances, although an abnormal polysaccharides was suggested by Matalon and accumulation of complex lipids is practically always Dorfman (1966). copyright. disclosed at least by the ultiastructural examination.
    [Show full text]